Efficacy and safety of ritlecitinib in vitiligo patients across Fitzpatrick skin types with biomarker analyses

Efficacy and safety of ritlecitinib in vitiligo patients across Fitzpatrick skin types with biomarker analyses

Efficacy and safety of ritlecitinib (an oral JAK3/TEC family kinase inhibitor) were evaluated in patients with nonsegmental vitiligo (NSV) across Fitzpatrick skin types (FSTs). Patients with FST I‐III (‘light skin’; n = 247) and FST IV‐VI (‘dark skin’; n = 117) received once‐daily ritlecitinib 50 mg...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Experimental dermatology 2024-09, Vol.33 (9), p.e15177-n/a
Hauptverfasser: Peeva, Elena, Yamaguchi, Yuji, Ye, Zhan, King, Brett, Picardo, Mauro, Sloan, Abigail, Ezzedine, Khaled, Del Duca, Ester, Estrada, Yeriel, Hassan‐Zahraee, Mina, He, Wen, Hyde, Craig, Bar, Johnathan, Facheris, Paola, Guttman‐Yassky, Emma
Format: Artikel
Sprache:eng
Schlagworte:
Adult
biomarkers
Biomarkers - blood
Biomarkers - metabolism
CXCL11 protein
Double-Blind Method
Drug therapy
Female
Fitzpatrick skin types
Humans
Interleukin-22
Interleukins - blood
Interleukins - metabolism
JAK inhibitor
Male
Middle Aged
Pigmentation
Placebos
Protein Kinase Inhibitors - administration & dosage
Protein Kinase Inhibitors - adverse effects
Protein Kinase Inhibitors - therapeutic use
ritlecitinib
Serum levels
Skin
Skin Pigmentation - drug effects
Treatment Outcome
Vitiligo
Vitiligo - drug therapy
Vitiligo - metabolism
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Efficacy and safety of ritlecitinib (an oral JAK3/TEC family kinase inhibitor) were evaluated in patients with nonsegmental vitiligo (NSV) across Fitzpatrick skin types (FSTs). Patients with FST I‐III (‘light skin’; n = 247) and FST IV‐VI (‘dark skin’; n = 117) received once‐daily ritlecitinib 50 mg (with/without 4‐week loading dose), low‐dose ritlecitinib or placebo for 24 weeks. At baseline, patients with light skin displayed higher CLM‐1 and NCR1 serum levels than patients with dark skin (p 
ISSN:0906-6705
1600-0625
1600-0625
DOI:10.1111/exd.15177